Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

In yesterday's presentation one thing I hadn't heard before is that 50% of Sprycel and Tasigna patients eventually progress. Tasigna and Sprycel combined currently generate $600mm in sales, however, that could grow significantly in coming years. And, with Gleevec coming off patent in 2015, Sprycel and Tasigna are already jockeying for first-line treatment approval which in turn would position AP534 as the defacto second line therapy.

http://www.novartis.com/newsroom/media-releases/en/2010/1421566.shtml

http://www.reuters.com/article/idUSN0413203020100605